UIC
NAGE

Uniplan Investment Counsel’s Niagen Bioscience NAGE Stock Holding History

Uniplan Investment Counsel’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-681,002
Closed -$4.27M – 140
2021
Q3 		$4.27M Buy
681,002
+1,737
+0.3% +$14.3K 0.26% 72
2021
Q2 		$6.7M Buy
679,265
+8,594
+1% +$74.9K 0.39% 48
2021
Q1 		$6.26M Sell
670,671
-412,453
-38% -$3.27M 0.4% 50
2020
Q4 		$5.2M Buy
1,083,124
+179,701
+20% +$876K 0.36% 56
2020
Q3 		$3.62M Buy
903,423
+136,757
+18% +$660K 0.25% 69
2020
Q2 		$3.52M Sell
766,666
-17,592
-2% -$78.8K 0.25% 67
2020
Q1 		$2.56M Buy
784,258
+109,154
+16% +$419K 0.19% 71
2019
Q4 		$2.91M Buy
675,104
+5,454
+0.8% +$19.4K 0.17% 93
2019
Q3 		$2.63M Sell
669,650
-35,580
-5% -$152K 0.16% 88
2019
Q2 		$3.28M Buy
+705,230
New +$3.01M 0.21% 82

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Uniplan Investment Counsel's NAGE Position: Q4 2021 in Review

Uniplan Investment Counsel sold out of Niagen Bioscience (NAGE) in Q4 2021, closing a stake of 681,002 shares — an estimated $4.27M sold.

Uniplan Investment Counsel first reported a position in NAGE in Q2 2019 and held it in 10 quarters. The position peaked at $6.7M in Q2 2021. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2021.

  • Uniplan Investment Counsel reported no remaining Niagen Bioscience position as of Q4 2021 after selling out during the quarter.
  • Uniplan Investment Counsel sold 681,002 Niagen Bioscience shares in Q4 2021, an estimated $4.27M.
  • Uniplan Investment Counsel first reported a position in Niagen Bioscience in Q2 2019 and held it in 10 quarters.
  • Uniplan Investment Counsel's Niagen Bioscience position peaked at $6.7M in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2021.

Based on Uniplan Investment Counsel's 13F filing for Q4 2021, filed 14 Feb 2022.